Newsroom
Press releases, peer-reviewed publications and conference presentations from BrainStorm Cell Therapeutics.
Latest from BrainStorm
BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced a major strategic expansion of its executive leadership team.
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science.
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of autologous stem cell therapies for neurodegenerative diseases, today announced that Peter J. Pitts has been appointed to the Company's Board of Directors, effective immediately.
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
May 19, 2026 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that in May it entered into definitive agreements for a private placement yielding gross proceeds of $400,000.
BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the three months ended March 31, 2026, and provided a corporate update.
Restoring Regulatory Fairness and Reclaiming Biomedical Leadership: ALS, Rare Disease Regulation, and the Future of Regenerative Medicine
Policy perspective on FDA regulation of ALS and regenerative medicine therapies, arguing for consistent evidentiary standards in rare and fatal disease.
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2025, and provided a corporate update.
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entered into a second definitive agreement for an additional $1 million strategic private placement. This brings the total capital raised in Februa
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entered into a definitive agreement for a strategic private placement of $1 million.
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a corporate update.
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update.
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
NEW YORK, Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the second quart
BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that it has received a delisting notification from The Nasdaq Stock Market LLC, informing the company that its common stock will be delisted from the Nasdaq Capital Market. Trading of BrainStorm's common stock on Nasdaq will be suspend
FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today acknowledged that the U.S. Food and Drug Administration's (FDA) consideration of a Citizen Petition requesting a new review of the data supporting NurOwn will p
BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival data from 10 participants in its Expanded Access Program (EAP) for NurOwn (autologous MSC-NTF cells) in amyotrophic lateral sclerosis (ALS)
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn Phase 3b ALS Clinical Trials
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) speciali
BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn for ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate its Phase 3b clinical trial of NurOwn (autologous MSC-NTF cells) fo
BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update.
BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has rescheduled the release of its financial results for the first quarter ended March 31, 2025, to post-market close today, May 15. In additi
BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2025, and provide a corporate up
BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in the 4th Annual ALS Drug Development Summit, to take place May 12-14, 2025, in Boston, MA. The company's senior leadership team will partici
BrainStorm's NurOwn Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, in collaboration with leading ALS research centers, today announced the acceptance of new pharmacogenomic data for oral presentation of new findings on NurOwn at the Internati
BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company developing cutting-edge cell therapies for neurodegenerative diseases, today announced the submission of an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA) for NurOwn, the compa
BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2024, and provided a corporate update.
BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases, today announced that it has been granted the exact compliance extension
BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update
NEW YORK, March 24, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the fourth qu
BrainStorm Issues 2024 Letter to Shareholders
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders.
BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update
, at 8:30 AM ET; Additionally, Key Opinion Leader Webinar on ALS Advancements to Take Place on December 11, 2024
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it has received Notice of Allowance from the U.S. Patent & Trademark Office (USPTO) for patent application 16/981,757 which covers its proprietar
BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will host a key opinion leader (KOL) webinar on Wednesday, December 11, 2024 at 10:00 AM ET. To register, click here.
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update.
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn Phase 3b Trial Manufacturing
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ: PLUR) through its wholly owned subsidiary ("Pluri"), an established global
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that on October 29, 2024, the Company received written notice from The Nasdaq Stock Market stating that the Company has regained compliance with the minimum clo
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn Expanded Access Program at 2024 Annual NEALS Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of two posters featuring NurOwn (MSC-NTF0 or debamestrocel) at the 2024 Annual Northeastern Amyotrophic Lateral Sclerosis Consortium (NEALS) M
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn Trial at the 2024 Maxim Healthcare Virtual Summit
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced its participation in the 2024 Maxim Healthcare Virtual Summit. Chaim Lebovits, President and CEO of BrainStorm, will join Jason McCarthy, Ph.D., Senior
BrainStorm Cell Therapeutics Announces Presentations on NurOwn at 2024 Annual NEALS Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the acceptance of two abstracts featuring NurOwn (MSC-NTF or Debamestrocel) at the 2024 Annual Northeastern Amyotrophic Lateral Sclerosis Consortium (NEALS) Me
BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the Second Quarter ended June 30, 2023 and provided a corporate update.
BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2024, and provide a corporate up
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a mid-year corporate update to discuss recent positive developments in the NurOwn program on Monday, July 8, at 8:00 a.m. U.S. East
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor (the "Holder") for the purchase and sale
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn Clinical Trial
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced it has reached alignment with the U.S. Food and Drug Administration (FDA) on the Chemistry, Manufacturing, and Controls (CMC) aspects of Brainstorm's
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of June 24, 2024.
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, will present new biomarker data suggesting that ALS patients may benefit from longer-term treatment with debamestrocel (NurOwn). The Company will share the data with
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the First Quarter ended March 31, 2024 and provided a corporate update.
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer. In addition, after four years of maintaining top executive role
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it received a notification letter (the "Notification Letter on Compliance") on April 10, 2024 from the Listing Qualifications Department of
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer-reviewed publication of Phase 3 biomarker data in Muscle and Nerve. The paper, entitled "Debamestrocel multimodal effects on biomarker pathways in amyo
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design for a Ph
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on the NurOwn program tomorrow, April 9, at 8:00 AM Eastern Time.
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.
Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes
Biomarker pathway analysis of debamestrocel-treated participants, linking multimodal biological effects to functional outcomes.
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn Trial Design at MDA Clinical and Scientific Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will present a poster (#M201) outlining the proposed design for a Phase 3b trial of NurOwn in amyotrophic lateral sclerosis (ALS) at the MDA
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA) for a Phase 3b study of NurOwn, its
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will provide a corporate update at the 17th Annual European Life Sciences CEO Forum to take place 28 - 29 of February, 2024 in Zurich, Switzer
BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today provided an update on the grant and allowance of three patent applications for NurOwn and NurOwn-Exosomes.
BrainStorm Issues 2023 Letter to Shareholders
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders.
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the completion of a productive meeting with the U.S. Food and Drug Administration (FDA) to discuss NurOwn, its investigational treatment for amyotrop
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the US Food & Drug Administration (US FDA) has granted the company a meeting to discuss the regulatory path forward for NurOwn in amyotrophic la
BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced a podium presentation and panel discussion at the 6th Annual ALS Research Symposium hosted by ALS ONE. The presentation will feature new analyses from the NurOw
BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.
BrainStorm to Announce Third Quarter 2023 Financial Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call on Tuesday, November 14th at 8:30 a.m. Eastern Time to discuss its financial results for the third quarter ended September 3
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn for the Treatment of ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced a strategic realignment to enable accelerated development of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). This realignment is des
BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the US Food and Drug Administration (FDA) has invited the Company to request an expedited face-to-face meeting to discuss the path forward for Nu
BrainStorm Cell Therapeutics Provides Update on FDA Advisory Committee Meeting to Review NurOwn for the Treatment of ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the outcome of the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee meeting to review the Biologics License
BrainStorm Cell Therapeutics Stock Trading Halted Today
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that Nasdaq has halted trading of the Company's common stock.
BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.
BrainStorm to Announce Second Quarter 2023 Financial Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2023, and provide a corporate update, at 8
Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 4,054,055 s
BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Bob Dagher, MD, as Executive Vice President and Chief Development Officer effective July 17, 2023. Dr. Dagher will serve on BrainStorm's exec
BrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of Neurodegeneration
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, this week presented new biomarker data from the Phase 3 trial of its late-stage investigational ALS treatment, NurOwn at the 2023 ALS and Related Motor Neuron Disease
BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Nir Naor, CPA, CFA, MBA (IMD), LL.M, as Board Member, chairman of its Audit Committee and member of its Governance, Nomination and
BrainStorm Cell Therapeutics to Participate in the Maxim Group Healthcare Virtual Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that Dr. Stacy Lindborg, Co-Chief Executive Officer, and Chaim Lebovits, President and Chief Executive Officer, will participate in a fireside chat at
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review NurOwn Biologics License Application Scheduled for September 27, 2023
NEW YORK, June 6, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) will convene a meeting of the Cellular, Tissue and Gene Therap
BrainStorm Cell Therapeutics Summarizes Key Messages from Its Participation as Expert Speakers in an Invited Presentation and Panel Discussion at The 2023 ALS Drug Development Summit
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, joined an international audience of patient advocacy groups, physicians, research organizations, industry representatives, key thought leaders and decision makers ded
BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the quarter ended March 31, 2023 and provided a corporate update.
BrainStorm to Announce First Quarter 2023 Financial Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the First Quarter ended March 31, 2023, and provide a corporate update, at 8
BrainStorm Cell Therapeutics Strengthens Leadership Team with Appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer (EVP, CMO), effective May 1, 2023. Dr. Taylor will serve o
BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2022 and provided a corporate update.
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn for the Treatment of ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) will hold an Advisory Committee Meeting ('ADCOM') to discuss the company's Biologics License Applicat
BrainStorm to Announce Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the fourth quarter and year ended December 31, 2022, and provide a corporate
BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn's Phase 3 ALS Study
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that BCLI will donate biospecimens from NurOwn's placebo-controlled Phase 3 ALS trial to the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS
BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that Chaim Lebovits, President and CEO, and Stacy Lindborg, Co-CEO, will jointly present a corporate and clinical overview at 10:30 a.m. PT on Monday,
BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Stacy Lindborg to the role of Co-Chief Executive Officer. This promotion launches a targeted capability build which will be led b
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted a Type A meeting to discuss the contents of a refusal to file letter previously issued re
BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the company has submitted a Type A Meeting Request to the U.S. Food and Drug Administration (FDA) to discuss the contents of a refusal to file le
BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a corporate update.
BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the company has received a refusal to file letter from the U.S. Food and Drug Administration (FDA) regarding the company's New Biologics License Applicatio
BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders on financial results for the third quarter ended September 30, 2022, and provide a corporat
BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of a poster with new analyses from NurOwn's placebo-controlled Phase 3 amyotrophic lateral sclerosis (ALS) trial that account for limitations i
BrainStorm Cell Therapeutics Presents NurOwn Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that a scientific abstract titled 'NurOwn (MSC-NTF) Phase 2 Clinical Trial in Progressive MS: Effects on CSF Neuroprotective Biomarkers' will be presented at th
BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the presentation of new biomarker analyses supporting the therapeutic benefit of NurOwn in amyotrophic lateral sclerosis (ALS) at the ongoing 5th Ann
BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn Phase 2 Progressive MS Trial in Multiple Sclerosis Journal
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer reviewed publication of data from the Phase 2 trial of NurOwn in progressive multiple sclerosis (MS) in Multiple Sclerosis Journal. The publication, en
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis
Results of the Phase 2 open-label study of repeat intrathecal administration of autologous MSC-NTF cells in progressive MS.
BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2022, and provided a corporate update. The company also announced its decision to submit a Bio
BrainStorm to Announce Second Quarter Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the second quarter, ended on June 30, 2022, and provide a corporate update,
Erratum to: A randomized placebo-controlled Phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis
Erratum to the Phase 3 primary publication.
Supplemental file with updated graphs from the Erratum
Supplementary figures accompanying the erratum to the Phase 3 publication.
BrainStorm Announces Presentations at June 2022 Scientific Conferences
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces presentations at forthcoming ALS and MS scientific conferences in June 2022. Insights into the ALS Phase 3 primary endpoint leveraging ENCALS model patient prog
BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the first quarter ended March 31, 2022 and provided a corporate update.
BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced two senior management appointments. Netta Blondheim Shraga, PhD has been appointed as VP, Research & Development, and Antal Pearl-Lendner, Adv. has been appointed to
BrainStorm Announces Presentation of NurOwn Exosome Preclinical Data at ISCT 2022 San Francisco Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "MSC-NTF derived small extracellular vesicles display superior macrophage immunomodulation compared with vesicles derived f
BrainStorm Announces Upcoming Scientific Conference Presentations
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces presentations at upcoming scientific conferences in May 2022. New data on the company's proprietary MSC-NTF exosome technology will be presented at ISCT 2022 (M
BrainStorm to Announce First Quarter 2022 Financial Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2022, and provide a corporate upd
Brainstorm Cell Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT
Brainstorm Cell Therapeutics (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative disease, announced today that the company President and Chief Medical Officer, Ralph Kern, MD MHSc has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group
BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate Update
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the fiscal year ended December 31, 2021 and provided a corporate update.
BrainStorm to Announce Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the fourth quarter and year ended December 31, 2021, and provide a
BrainStorm Cell Therapeutics Abstract Selected as Late-Breaking Presentation at the 2022 MDA Clinical & Scientific Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the acceptance of a scientific abstract as a late-breaking oral presentation at the 2022 MDA (Muscular Dystrophy Association) Clinical & Scientific Co
Brainstorm Cell Therapeutics Announces Grant of a New Brazilian Patent Covering Methods of Manufacturing NurOwn
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Brazilian Patent Office has granted the patent application titled: "A method of generating cells which secrete Brain Derived Neurotrophic Fac
BrainStorm Cell Therapeutics to Present at the 12th Annual California ALS Research Summit
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D., MHSc, President and Chief Medical Officer of BrainStorm Cell Therapeutics, will provide a corporate and clinical overview at th
BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D. MHSc, President and Chief Medical Officer of Brainstorm Cell Therapeutics, will provide a corporate and clinical overview at Bio
FDA Authorizes Further NurOwn Dosing Under Expanded Access Program
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced plans for a dosing extension of NurOwn for participants who completed the Expanded Access Protocol (EAP). The U.S. Food and Drug Administration (FDA) recommend
BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's® Phase 3 Study for ALS in Muscle and Nerve
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer reviewed publication of Phase 3 clinical data in Muscle and Nerve. The paper, entitled "A Randomized Placebo-Controlled Phase 3 Study of Mesenchymal St
BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn Manufacturing
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, and Catalent (NYSE: CTLT), a global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatmen
BrainStorm Cell Therapeutics to Present New Biomarker Data on NurOwn at the International Symposium on ALS/MND
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that biomarker data on NurOwn will be presented at the 32nd International Symposium on ALS/MND, to be held virtually 7-10 December 2021. The presentation "NurO
A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis
The Phase 3 primary publication. The primary endpoint was not met; a pre-specified analysis of participants with baseline ALSFRS-R ≥ 35 showed a clinical response at 28 weeks.
BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn in ALS at the 4th Annual ALS ONE Research Symposium
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of new analyses from the Phase 3 trial of NurOwn at the 4th Annual ALS ONE Research Symposium. The presentation, which will be delivered Tomorr
BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced financial results for the quarter ended September 30, 2021, and provided a corporate update.
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced executive appointments as the company prepares for future growth. Sidney A. Spector, MD, PhD, was named Senior Vice President Global Strategy and Medical Affair
Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to Board of Directors
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Menghis Bairu, MD, to the company's Board of Directors. The appointment becomes effective on October 28, 20221.
BrainStorm to Announce Third Quarter Financial Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the third quarter ended September 30, 2021, and provide a corporate
BrainStorm Announces Scientific Presentation of NurOwn Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Therapeutic Benefits of MSC-NTF (NurOwn) Exosomes in Acute Lung Injury Models" at the NYSCF 2021 VIRTUAL Meeting, being h
Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, will present findings from a multicenter, open label clinical trial of NurOwn in progressive multiple sclerosis. The study, "Phase 2 Safety and Efficacy Study of Intrathecal M
BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "CSF biomarker correlations with primary outcome in NurOwn Phase 3 clinical trial" will be presented as a scientific poster at
BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that Stacy Lindborg, Ph.D., Executive Vice President and Head of Global Clinical Research, will deliver a presentation at the 2021 Cell & Gene Meeting on the Me
BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "Phase 2 Safety and Efficacy Study of Intrathecal MSC-NTF cells in Progressive Multiple Sclerosis" will be presented in an ora
Therapeutic benefits of MSC-NTF (NurOwn) exosomes in acute lung injury models
Poster presented at the 2021 New York Stem Cell Foundation conference.
CSF biomarker correlations with primary outcome in NurOwn Phase 3 clinical trial
Poster presented at the 2021 Annual NEALS Meeting on cerebrospinal fluid biomarker correlations with the Phase 3 primary outcome, which was not met.
BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended June 30, 2021 and provided a corporate update.
BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that is has received Good Manufacturing Practice (GMP) approval from the Israel Ministry of Health for three state-of-the-art cleanrooms leased by the Company a
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2021, and provide a corporate upd
Brainstorm Announces Expansion of NurOwn IP Portfolio with Grant and Allowance of Multiple Patents and Applications in Major Markets
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant and/or allowance of a series of patents and patent applications. These patents and patent applications, which were granted/allowed in 2020 a
BrainStorm Announces Scientific Presentation of NurOwn Exosome Preclinical ARDS Data at ISCT 2021 New Orleans VIRTUAL Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Molecular Mechanisms Underlying MSC-NTF (NurOwn) Exosome Benefits in a Mouse LPS-induced ARDS Model" at the ISCT 2021 New
BrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31, 2021 and provided a corporate update.
BrainStorm to Announce First Quarter Financial Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2021, and provide a corporate upd
BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn as a Treatment for Progressive MS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Company's Phase 2 trial evaluating three repeated administrations of NurOwn (MSC-NTF cells), each given 2 months apart, as a treat
BrainStorm to Present at SVB Leerink 10th Global Healthcare Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that members of the management team will participate in the 10th Annual SVB Leerink Global Healthcare Conference.
BrainStorm Announces High-Level FDA Feedback on NurOwn ALS Clinical Development Program
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from
BrainStorm Announces Feedback from FDA Type-C Meeting on Future NurOwn Manufacturing Plan
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently concluded a Type C meeting with the U.S. Food and Drug Administration (FDA) to review specific aspects of the company's planned manufact
BrainStorm Announces Full Year 2020 Financial Results and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the fiscal year ended December 31, 2020, and provided a corporate update.
BrainStorm-Cell Therapeutics to Announce Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update
BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the fourth quarter and ye
BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn Derived Exosome-Based Treatment for COVID-19 ARDS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the peer-reviewed publication of a preclinical study in the journal Stem Cell and Research Therapy. The study, entitled "MSC-NTF (NurOwn) exosomes: a no
MSC-NTF (NurOwn) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model
Peer-reviewed paper on MSC-NTF (NurOwn) exosomes as a therapeutic modality in the mouse LPS-induced ARDS model.
BrainStorm Issues 2020 Letter to Shareholders
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the following letter from its Chief Executive Officer, Chaim Lebovits, to its shareholders and the investment community.
BrainStorm Announces Completion of All Dosing in NurOwn Phase 2 MS Study
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that all dosing has been completed in the ongoing Phase 2 trial evaluating NurOwn (MSC-NTF cells) as a treatment for progressive MS. The Phase 2 open-la
BrainStorm Announces NurOwn Expanded Access Program
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today the initiation of a NurOwn (MSC-NTF cells) Expanded Access Program (EAP) for patients with amyotrophic lateral sclero
BrainStorm to present NurOwn Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that results from the Company's placebo controlled, randomized, double-blind Phase 3 trial evaluating NurOwn (MSC-NTF cells) as a treatment for ALS will
BrainStorm Announces Topline Results from NurOwn Phase 3 ALS Study
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the Company's randomized, double-blind placebo-controlled Phase 3 trial evaluating NurOwn (MSC-NTF cells) as a treatment for Amyotr
Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's U.S. Manufacturing Facility
Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that BrainStorm has selected RR&D as its partner to expedite site selection and
Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn
Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI), a leading developer of cellular therapies f
BrainStorm Announces Scientific Presentation of NurOwn Exosome Preclinical ARDS Outcomes at the Virtual New York Stem Cell Foundation Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced the presentation of a poster titled, "MSC-NTF (NurOwn) Exosomes: A Novel Therapeutic Modality in the Mouse LPS-induced ARDS model Analysis" at the NYSCF Confe
BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the third quarter ended September 30, 2020, and provided a corporate update.
BrainStorm to Present at the 2020 Cell & Gene Meeting on the Mesa
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Stacy Lindborg, Ph.D., Executive Vice President and Head of Global Clinical Research, will deliver a presentation at the 2020 Cell & Gene Meeting on the
BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Corporate Update
BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the third quarter ended S
BrainStorm Announces Scientific Presentation at the Annual NEALS Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced the presentation of a poster titled, "Advancing NurOwn for ALS: Phase 3 Clinical Trial Design" at the Annual Northeast ALS (NEALS) Meeting, being held virtual
BrainStorm Appoints William K. White as Senior Vice President, Head of Market Access & Pricing
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the appointment of William K. White as senior vice president, head of market access and pricing. Mr. White has more than 25 years' experience in leading
Brainstorm Announces Grant of a New Japanese Patent for NurOwn
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Japanese Patent Office (JPO) has granted Brainstorm's Japanese Patent, number: 6,753,887, titled: 'Methods of Generating Mesenchymal Stem Cel
BrainStorm to Present at Scientific Conferences in September
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it will deliver virtual presentations during Advanced Therapies & Expo 2020, September 9, at the 2020 CIRM Grantee Meeting, September 14, 2020, and
BrainStorm Appoints Pharmaceutical Veteran Anthony Waclawski as Executive Vice President, Global Head of Regulatory Affairs
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the appointment of Anthony P. Waclawski, Ph.D. as Executive Vice President, Global Head of Regulatory Affairs. Dr. Waclawski is an industry veteran and a
BrainStorm to Present Data Linking MRI Measures to Functional Improvement in Progressive Multiple Sclerosis (MS)
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the acceptance of a clinical abstract documenting an association between magnetic resonance imaging (MRI) measures and functional improvement in patients
BrainStorm Announces Publication of New Preclinical Data Supporting Proposed NurOwn Mechanism in ALS, Progressive MS and Alzheimer's Disease
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the publication of a manuscript titled, "Effects of MSC-NTF cells on T and B regulatory cell function in ALS" in the journal Amyotrophic Lateral Sclerosi
BrainStorm to Present at the 40th Annual Canaccord Genuity Growth Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Ralph Kern, MD, MHSc, President and Chief Medical Officer, will present a corporate overview during the 40th Annual Canaccord Genuity Growth Conference,
BrainStorm Announces Financial Results for the Second Quarter of 2020 and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the second quarter and first half ended June 30, 2020, and provided a corporate update.
Effects of MSC-NTF cells on T and B regulatory cell function in ALS
Peer-reviewed paper on the effects of MSC-NTF cells on T and B regulatory cell function in ALS.
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update
BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the second quarter ended
BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn derived Exosome-Based Treatment for COVID-19 ARDS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it has successfully completed its first milestone in developing an innovative exosome-based platform-technology for the treatment severe COVID-19 in
BrainStorm Hosting KOL Webinar to Discuss NurOwn Phase 2 Alzheimer's Disease Program
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, is hosting a Key Opinion Leader (KOL) webinar on its Alzheimer's Disease (AD) program today at 8:15 AM Eastern Time. The Company recently announced that it is expanding
BrainStorm Announces Completion of All Dosing in NurOwn Phase 3 Clinical Trial in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that final participant dosing has been administered in the Phase 3 pivotal trial of NurOwn (MSC-NTF cells) in amyotrophic lateral sclerosis (ALS). The t
BrainStorm to Showcase Alzheimer's Disease Clinical Program in KOL Webinar
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, will hold a Key Opinion Leader (KOL) webinar on the Company's Alzheimer's disease (AD) clinical program on Wednesday July 8th at 8.15am ET. The Company recently announce
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn for the Treatment of Alzheimer's Disease
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced a new clinical program focused on the development of NurOwn as a treatment for Alzheimer's disease. As part of the newly announced program, the Company
BrainStorm Cell Therapeutics to Join the Russell 2000® Index and Russell 3000® Index
BrainStorm Cell Therapeutics Inc. (NasdaqCM: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that its shares will join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconst
BrainStorm Granted SME Status by the European Medicines Agency
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has been granted Small and Medium-Sized Enterprise (SME) status by the European Medicines Agency’s (EMA) Micro, Small and Medium-Sized Enterprise
BrainStorm to Present at the Raymond James Human Health Innovations Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Chaim Lebovits, CEO and Ralph Kern, MD, MHSc, President and Chief Medical Officer, will present a corporate overview on Thursday, June 18 at 9:00 am EST,
The ALS Association, I AM ALS Award BrainStorm Cell Therapeutics $500,000 for ALS Biomarker Study
The ALS Association and I AM ALS announced today that the organizations have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics (NASDAQ: BCLI), a biotechnology company, to support an amyotrophic lateral sclerosis (ALS) biomarker research study. The grant will be used to draw insigh
BrainStorm to Participate in BIO Digital 2020
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Dr. Ralph Kern, M.D, President and Chief Medical Officer will present a corporate overview during the BIO International Convention, which has transitione
BrainStorm Announces that Pivotal Phase 3 Trial Remains on Track for Topline Data in Q4-2020
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today an update on the Company's Phase 3 pivotal trial investigating NurOwn in ALS. The Company continues to expect that top-line data from the trial will be
BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that Stacy R. Lindborg, Ph.D. has been appointed Executive Vice President Head of Global Clinical Research effective June 1, 2020. Dr. Lindborg is an exp
BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31, 2020 and recent corporate updates.
BrainStorm Presents New Data Highlighting NurOwn Immunomodulation in Neurology
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that new data highlighting the immunomodulatory effects of NurOwn on B and T regulatory function appeared in an online supplement to Neurology.
BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update
BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today, that the Company will hold a conference call to update shareholders on financial results for the first quarter ended
BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded a new grant of approximately $1.5 million by the Israel Innovati
David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer
BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that David Setboun, Pharm.D., MBA, has been appointed Executive Vice President and Chief Operating Officer.
BrainStorm Appoints Renowned Distinguished Economist, Prof. Jacob Frenkel, Chairman of the Board of Directors
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced the appointment of Jacob Frenkel, Ph.D., as Chairman of the Board of Directors. Prof. Frenkel, a world-renowned economist and former Governor of the Bank of Isra
BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, will hold a conference call on Wednesday, March 18th at 08:30 am Eastern Time, to update shareholders on the steps taken in order to e
BrainStorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share
BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced that it has entered into a definitive agreement with Abbhi Investments, LLC, a healthcare-focused family office based in Miami, Florida, in connection with a pr
Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that Partners MS Center at Brigham and Women’s Hospital, a leading research and clinical care center, has contracted w
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces financial results for fiscal year ended December 31, 2019.
BrainStorm’s Chief Operating Officer to Present at Noble Capital Markets’ Sixteenth Annual Investor Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases, announced that Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, will provide a clinical update on the Company’s ALS and M
BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn Regulatory Pathway for Approval in ALS
BrainStorm Cell Therapeutics, Inc., (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company recently held a high level meeting with the U.S. Food and Drug Administration (FDA) to discuss potential NurOwn regulatory pathways fo
BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update
BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company will hold a conference call to update shareholders on financial results for the fourth quarter and full year ended December 31, 2019, an
BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits, CEO and President, will provide an update of the Company’s ALS and MS trials and company growth strategy at
BrainStorm Receives Notice of Intention to Grant Additional EU patent for NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office (EPO) has communicated its intention to grant a European patent titled 'Methods of Generating Mesenchymal Stem Cells w
BrainStorm Cell Therapeutic’s COO and CMO, Dr. Ralph Kern, to Present at the 10th Annual California ALS Research Summit
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, will present at the 10th Annual California ALS Research Summit, January
BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President and Chief Executive Officer, will provide a corporate overview at the 2020 Biotech Showcase, being held on January 13-1
NurOwn Data Safety Monitoring Board Recommends MS Phase 2 Clinical Trial Continue
BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the clinical trial independent Data Safety Monitoring Board (DSMB) has completed the first, pre-specified interim analysis, of safety outcomes for 9 parti
BrainStorm Issues 2019 Letter to Shareholders
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapeutics for neurodegenerative diseases, today issued a Letter to Shareholders.
BrainStorm Selected as Buzz of BIO 2020 Winner
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced, that it was selected as the Buzz of BIO, in the Public Therapeutics Biotech category, and due to extensive vo
BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company is proud to be a gold sponsor of the 30th International Symposium on ALS/MND.
BrainStorm Announces the Mount Sinai Medical Center as a Progressive MS Phase 2 Clinical Trial Site
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that The Mount Sinai Medical Center, internationally acclaimed for its excellence in research, patient care, and educa
BrainStorm Cell Therapeutics Announces Publication of NurOwn ALS Phase 2 Randomized Clinical Trial Data in Neurology
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced publication of “NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results,” in t
BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update
A webcast replay of the conference call will be available for 30 days on the “Investors & Media” page of BrainStorm’s website:
BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Society
BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that the Company has received a $495,330 grant from the National Multiple Sclerosis Society, through its Fast Forward program, to advance BrainStorm’s Ph
BrainStorm Announces Grant of a New Japanese Patent for NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Japan Patent Office (JPO) has issued a Decision to Grant a Patent for BrainStorm's Patent Application, number: 2016-548691, titled: ‘Method o
BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting
BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company’s Chief Operating and Chief Medical Officer Ralph Kern MD MHSc will present at the 7th International Stem Cell Meeting, which is hosted
BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update
BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company will hold a conference call to update shareholders on financial results for the third quarter ended September 30, 2019, and provide a co
NurOwn, phase 2, randomized, clinical trial in patients with ALS
The primary publication of the randomized, placebo-controlled Phase 2 study of NurOwn in participants with ALS.
NurOwn Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue
BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Phase 3 clinical trial independent Data Safety Monitoring Board (DSMB) has completed the second, pre-specified interim analysis, of safety outc
BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that it will be presenting at the Dawson James Securities 5th Annual Small Cap Growth Conference, being held o
BrainStorm Cell Therapeutics’ President and CEO to be Featured as Keynote Speaker at Cell Series UK 2019
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced, Chaim Lebovits, President and CEO, will serve as a Keynote Speaker at Cell Series UK. Cell Series UK, will be
BrainStorm Cell Therapeutics Presentations at Neuromuscular Drug Development Summit
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, will be participating and presenting scientific data at the upcoming Neuromuscular Drug Development Summit, from October 23-25
BrainStorm’s NurOwn Phase 3 ALS Clinical Trial Now Fully Enrolled
BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it has fully enrolled the 200-patient Phase 3 clinical trial evaluating repeat intrathecal administration of NurOwn Cellular Therapeutic (autologo
BrainStorm Announces Notice of US Patent Allowance for NurOwn Cellular Therapeutic Technology Platform
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for BrainStorm's new US Patent Application, number: 15/113
BrainStorm Cell Therapeutics to Present NurOwn Phase 2 Biomarker Data at North East Amyotrophic Lateral Sclerosis (NEALS) 18th Annual Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases announced today, Chief Operating Officer and Chief Medical Officer, Ralph Kern, MD, MHSc, will present NurOwn Phase 2 biomarke
BrainStorm Cell Therapeutics Announces Support for FDA Guidelines on ALS Drug Development
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases supports the US FDA’s publication on September 24, 2019 of “Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guida
BrainStorm Strengthens Senior Executive Management Team with the Appointment of Preetam Shah, Ph.D., M.B.A., as Chief Financial Officer
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that Preetam Shah, Ph.D., M.B.A., has been appointed Chief Financial Officer effective September 6, 2019.
BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, will present scientific data at the 35thCongress of the European Committee for Treatment and Research in Multiple Sclerosis (E
BrainStorm Announces Financial Results for the Second Quarter of 2019 and Provides a Corporate Update
Conference Call and Webcast: Tuesday, August 13, 2019 @ 8:00 a.m. Eastern Time
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Comprehensive Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today, that the Company will hold a conference call to update shareholders on financial results for the second quarter ended
Third Clinical Site Initiated for BrainStorm Cell Therapeutic’s Phase 2 Progressive MS Study
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company has contracted with the Keck School of Medicine of The University of Southern California and its acad
BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, yesterday, on World MS Day, presented a poster of the Company’s “Phase 2 Open-Label, Multicenter Study of Repeated Intrathecal Adminis
BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that the Stanford University School of Medicine will serve as the second contracted clinical study site for the Compan
BrainStorm Senior Management to Present at BIO 2019
BrainStorm-Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative disease, today announced members of the Senior Management Team will have an expanded presence at BIO International Convention 2019 held in Philadelphia, June 3-6.
BrainStorm Issues Statement (Italian Translation Included)
, -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, issues today the following statement: Recently, numerous organizations approached BrainStorm Cell Therapeutics informing manageme
BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, president and CEO, will provide an update on the Company’s two clinical trials of NurOwn (the Phase 3 study in amyotrophic later
BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31, 2019 and recent corporate updates.
Phase 2 open-label, multicenter study of repeated intrathecal administration of autologous MSC-NTF cells in progressive multiple sclerosis
Conference presentation of the Phase 2 open-label study of repeat intrathecal administration of autologous MSC-NTF cells in progressive multiple sclerosis.
Molecular characterization of VEGF secretion by MSC-NTF cells (NurOwn): therapeutic implications in ALS
Poster presented at the 2019 Annual AAN Meeting on the molecular characterization of VEGF secretion by MSC-NTF cells.
Modulation of CSF caspase-3 in MSC-NTF cells (NurOwn) in a Phase 2 ALS study: correlations with CSF biomarkers and clinical response
Poster presented at the 2019 Annual AAN Meeting on the modulation of cerebrospinal fluid caspase-3 in the Phase 2 ALS study.
BrainStorm’s Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases
Brainstorm-Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative disease, today announced that it has expanded its proprietary cellular technology platform to include NurOwn-derived exosomes for potential development across a broad range o
Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that two scientific abstracts have been accepted for presentation at the 71stAmerican Academy of Neurology (AAN) Annua
BrainStorm Announces Grant of an additional New European Patent for NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office ("EPO") has granted a European-wide patent titled 'Mesenchymal Stem Cells for the treatment of CNS Diseases.' The Euro
BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the first patient has been enrolled in its Phase 2 open-label, multicenter study of repeated intrathecal administ
BrainStorm to Host Business Update Conference Call
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, will hold a conference call on Tuesday, March 12th, at 08:30am Eastern Daylight Time, to update shareholders on the Company’s overall
BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today Cleveland Clinic as the first U.S. clinical site contracted for a planned Phase 2 open-label, multicenter study of rep
BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits, CEO will present at the 2019 Sachs Associates European Life Sciences CEO Forum on February 25-26,
BrainStorm Issues a Statement to Patients and Shareholders
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, in response to numerous requests, issues today the following statement:
BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits, CEO, will provide a corporate presentation at the BIO CEO & Investor Conference on February 11, 2
BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits, CEO will provide a corporate overview presentation at the NobleCon15 Investor Conference in Fort
BrainStorm Granted Additional Patent for NurOwn in Israel
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative diseases, today announced that the Israel Patent Office has granted an additional patent titled “Methods of Generating Mesenchymal Stem Cells which Sec
BrainStorm to Present NurOwn Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today announced that Ralph Kern MD, MHSc, Chief Operating Officer and Chief Medical Officer, will provide a clinical update
BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President and Chief Executive Officer, will provide a corporate overview at the 2019 Biotech Showcase, being held on January 7-9,
BrainStorm Issues 2018 Letter to Shareholders
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders.
BrainStorm Expands Manufacturing of NurOwn for Phase 2 Progressive MS Trial
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has expanded its autologous cell manufacturing capacity to produce NurOwn to support clinical trials in additional indications, including a P
FDA Accepts BrainStorm’s NurOwn IND Application for Progressive Multiple Sclerosis
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application to ini
BrainStorm Cell Therapeutics to Present at the 29th International Symposium on ALS/MND
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today that a poster presentation highlighting a comprehensive review of ALS clinical trial enrichment strategies will be
A systematic review of enrichment strategies for current clinical trials in ALS
Poster presented at the International Symposium on ALS/MND reviewing enrichment strategies used in current ALS clinical trials.
BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn in Progressive Multiple Sclerosis
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA
BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today that it will highlight progress with ongoing preclinical research and their proprietary NurOwn technology platform
BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today financial results for the third quarter and nine months ended September 30, 2018.
BrainStorm to Announce Third Quarter Financial Results and Provide Corporate Update on Monday, October 29
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the third quarter ended September 30, 2018, and provide a corporate update, on Monday, October 29 at 8:30am Eastern Time.
BrainStorm Poster Receives Clinical Abstract Award at NEALS Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today that their scientific abstract presented by Dr. James Berry entitled, “MicroRNA Changes in the NurOwn Phase 2 ALS
BrainStorm Highlights Translational Data and Presentations Supporting NUROWN® Technology Platform as a Best-In-Class Strategy in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today that members of its executive team will present at the Northeast Amyotrophic Lateral Sclerosis (NEALS) Conference in Clearwate
MicroRNA changes in the NurOwn Phase 2 ALS randomized clinical trial: relationship to neuroprotection and innate immunity
Poster presented at the Annual NEALS Conference on microRNA changes in the Phase 2 ALS randomized clinical trial.
BrainStorm Granted New U.S. Patent for Industrial Scale Manufacturing of NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the United States Patent Office (USPTO) has granted a new US patent titled 'METHODS OF GENERATING MESENCHYMAL STEM CELLS WHICH SECRETE NEUROTROPH
BrainStorm to Present at FDA and Scientific Workshops Highlighting Innovation in ALS Trial Designs and Continued Progress with NurOwn Cellular Therapy Platform
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today that members of BrainStorm’s executive team will present and participate on expert panel discussions with industry leaders in Cell & Gene
BrainStorm Cell Therapeutics Announces New Presentation Time at the H.C. Wainwright & Co. 20th Annual Investor Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present a corporate overview at the H.C. Wainwright & Co. 20th Annual Investor Conference, on Thursday, September 6th at 2:10pm
BrainStorm Appoints Arturo Araya as Chief Commercial Officer
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that is has appointed Arturo O. Araya, M.A., M.B.A., as Chief Commercial Officer, effective immediately. Mr. Araya brings to the BrainStorm team nearl
BrainStorm Cell Therapeutics to Provide Corporate Update at the H.C. Wainwright & Co 20th Annual Investor Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present a corporate overview at the H.C. Wainwright & Co. 20th Annual Investor Conference, taking place September 4-6, 2018, at
BrainStorm Cell Therapeutics Announces Successful Interim Safety Analysis in Phase 3 Trial of NurOwn Therapy for ALS
BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has completed the pre-specified interim analysis of safety outcomes for the first 31 participan
BrainStorm Announces Grant of a New European Patent for NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office ("EPO") has grante
BrainStorm to Announce Second Quarter Financial Results of 2018 and Provide a Corporate Update on Monday July 23
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the second quarter ended June 30, 2018, and provide a corporate update, on Monday, July 23 at 8:30am Eastern Time.
BrainStorm Granted Japanese Patent for NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has received a Decision to Grant notice from the Japanese Patent Office ("JPO") to issue a patent entitled: "Methods of generating mesenchymal
BrainStorm Announces Second U.S. Manufacturing Site for NurOwn Production
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has contracted with the Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute (Dana-Farber) as a secon
BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Joseph Petroziello as vice president of scientific & corporate communications, and Susan Ward, Ph.D. as head of clinical operations
BrainStorm Provides Update on "Right to Try" Policy
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that after careful evaluation of the newly enacted "Right to Try" (RTT) Act, it will not make NurOwn available under this legislation at this time. T
BrainStorm to Host Tomorrow a Conference Call to Announce Its "Right To Try" Policy
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call tomorrow, June 26 th at 08:30am Eastern Time, to announce its policy in regards to the "Right To Try" legislation.
BrainStorm Announces Exercise of Warrants Resulting in Cash Proceeds of ~$12.3 Million at $5 Share
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has entered into a Warrant Exercise Agreement with certain holders of warrants issued in the January 8, 2015 private placement. These holders have e
BrainStorm to Host Call Following President Trump's Citing of Company's ALS Treatment During "Right-to-Try" Bill Signing
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that the company will host a "Right-to-Try" (RTT) discussion call on Thursday, June 7th at 8:15am EDT.
BrainStorm Cell Therapeutics to Provide Corporate Update at the BIO International Convention
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present a corporate overview at the BIO International Convention, taking place June 4-7 in Boston, Massachusetts.
BrainStorm Cell Therapeutics Issues Statement on "Right to Try" Legislation
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issues a statement following Congress passing the Federal "Right-to-Try" bill. The "Right-to-Try" bill will enable terminally ill patients who do not meet clini
BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical Highlights
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31, 2018.
BrainStorm CEO to Present at World Advanced Therapy and Regenerative Medicine Congress in London
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, president and CEO, will present data from the company's Phase 2 clinical study of NurOwn in amyotrophic lateral sclerosis (ALS),
Brainstorm to Announce First Quarter Financial Results and Provide Corporate Update on Monday, May 14
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call to discuss its financial results for the first quarter ended March 31, 2018, and provide important corporate updates, on Monday, May 14 at
BrainStorm Cell Therapeutics to Participate in Movement Disorder Panel at the Neurotech Investing and Partnering Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that Ralph Kern, M.D., MHSc, Chief Operating Officer and Chief Medical Officer, will be a panelist at the 13th Annual Neurotech Investing & Partnering Co
BrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New York
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will present at the Alliance for Regenerative Medicine's (ARM) 6th Annual Cell & Gene Therapy Investor D
Modulation of CSF miRNAs in ALS Phase 2 study participants treated with MSC-NTF cells (NurOwn)
Poster presented at the Annual AAN Meeting on the modulation of cerebrospinal fluid miRNAs in ALS Phase 2 study participants.
NurOwn Phase 2 ALS trial: ALSFRS-R improvement is reflected in subscale domains
Poster presented at the Annual AAN Meeting on the ALSFRS-R subscale domains recorded in the Phase 2 ALS trial.
BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn in ALS Now Open to Canadian Patients
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announces that it has amended the protocol of its Phase 3 clinical trial of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). Per the protocol a
BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced the appointments of Stanley H. Appel, M.D., and Amit Bar-Or, M.D., to its scientific advisory board (SAB). Dr. Appel and Dr. Bar-Or are joining Jerold Ch
BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President & Chief Executive Officer, and Dr. Ralph Kern, M.D., PhD., Chief Operating Officer & Chief Medical Officer, will provid
BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to Chair
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today the formation of its Scientific Advisory Board (SAB) and the appointment of Jerold Chun, M.D., Ph.D., to Chair. Chun is an acclaimed neuroscientist an
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces financial results for the fourth quarter and fiscal year ended December 31, 2017.
BrainStorm to Host an Annual Financial Results Call and Provide a Corporate Update on Thursday, March 8
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call on Thursday, March 8 to discuss financial results for the calendar year ended December 31, 2017, and provide important corporate updates.
BrainStorm's NurOwn Phase 2 ALS Clinical Trial and Biomarker Abstracts Accepted for Platform Presentations at the 70th Annual American Academy of Neurology Meeting in Los Angeles, California
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that two scientific posters describing ALSFRS-R subgroup analyses and innovative micro-RNA biomarker data from the NurOwn ® Phase 2 randomized double-
BrainStorm Cell Therapeutics to Present at the BIO CEO & Investor Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President & Chief Executive Officer, will provide a corporate overview at the BIO CEO & Investor Conference, being held February
BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today the appointment of Anthony (Tony) Polverino, Ph.D., to its board of directors. Dr. Polverino is a highly accomplished senior biopharmaceutical executi
BrainStorm to Present at Precision Medicine World Conference 2018 Silicon Valley on January 22
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits, President & CEO, and Dr. Ralph Kern, COO & CMO, will be presenting at Precision Medicine World Conference (PMWC) 2018 Silicon Vall
BrainStorm Granted GMP Certification for a Marketing-Level Manufacturing of NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has received Good Manufacturing Practice (GMP) approval from the Israel Ministry of Health (MoH) for its Israeli contract manufacturing facility. T
Brainstorm Issues 2017 Letter to Shareholders
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to Shareholders from its President and CEO, Chaim Lebovits
BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech Showcase
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide a corporate overview at the 10th Annual Biotech Showcase, being held on January 8-10, 2018
BrainStorm's Abstracts on Phase 2 NurOwn Biomarkers Accepted for Presentation at the International Symposium on ALS/MND in Boston
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that two scientific posters describing innovative biomarker data from the NurOwn Phase 2 randomized double-blind placebo-controlled study will be pre
New Peer Reviewed Publication Shows That BrainStorm's NurOwn Has a Unique miRNA Signature
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that a study profiling NurOwn's unique miRNA signature has been published online in the peer-reviewed journal Stem Cell Research & Therapy . The publ
BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Eyal Rubin as Chief Financial Officer. Mr. Rubin will be responsible for all corporate finance and accounting activities for Bra
miRNA profiling of NurOwn: mesenchymal stem cells secreting neurotrophic factors
Peer-reviewed miRNA profiling of NurOwn, the mesenchymal stem cells induced to secrete neurotrophic factors.
BrainStorm Expands Its Patent Portfolio to Include a New US Patent For Its NurOwn Technology for Parkinson's Disease And ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has received Notice of Allowance from the United States Patent Office for US Patent Application No.: 14/173,846 titled "ISOLATED CELLS AND POPULATIO
BrainStorm Announces Third Quarter 2017 Financial Results
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced financial results for the third quarter ending September 30, 2017.
BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS) at the Massachusetts General Hospital and UC Irvine Medical Center in California.
Brainstorm to Announce Third Quarter Financial Results And Provide Corporate Updates on Tuesday, October 17
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the three and nine months ended September 30, 2017, and provide important corporate updates, on Tuesday, October 17.
BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases announced today that it will be presenting at the 2017 Disruptive Growth Company Showcase NYC at 4 PM EDT/ 1 PM PDT on September 27, 2017 at the Grand Hyatt 109 E 42nd
BrainStorm Announces Second Quarter 2017 Financial Results
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the second quarter ending June 30, 2017.
BrainStorm Announces Second Quarter 2017 Financial Results
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the second quarter ending June 30, 2017.
Brainstorm to Host Second-Quarter 2017 Earnings Teleconference and Provide Important Corporate Updates, on Wednesday, August 16
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the three and six months ended June 30, 2017 and provide important corporate updates on Wednesday, August 16 th.
BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government Affairs
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today the appointment of Mary Kay Turner to the position of Vice President of Patient Advocacy and Government Affairs, effective August 7, 2017. Ms. Turner
BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed a definitive agreement with the University of California Irvine Medical Center (UCI) to enroll patients in the planned Phase 3 clin
Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn in ALS
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded Brainstorm a grant of $16 million to support the pivotal Phase 3 study of N
BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed definitive agreements with Massachusetts General Hospital and California Pacific Medical Center (CPMC) to enroll patients in the pl
Worldwide Clinical Trials Selected by BrainStorm as CRO for Phase 3 NurOwn Trial in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has selected Worldwide Clinical Trials ("Worldwide") as its Clinical Research Organization (CRO) for its planned Phase 3 study of NurOwn in t
BrainStorm to Provide Corporate Update at the BIO International Convention
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Company will present a corporate overview at the BIO International Convention, taking place June 19-22 at the San Diego Convention Center in
BrainStorm Awarded $2.1 Million Non-Dilutive Grant for 2017 by the Israel Innovation Authority
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded a new grant of approximately $2.1 million by the Israel Innovati
BrainStorm to Present at Cell & Gene Exchange Conference in Washington DC
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the Company will present data from its Phase 2 clinical study of NurOwn in amyotrophic lateral sclerosis (ALS) at the Inaugural "Cell & Gene Exchange"
BrainStorm Initiated Technology Transfer to City of Hope for U.S. Production of NurOwn for Phase 3 ALS Study
HACKENSACK, N.J., PETACH TIKVA, Israel and DUARTE, Calif., May 16, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has begun training the cell manufacturing team at City
BrainStorm Announces First Quarter 2017 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the first quarter ending March 31, 2017.
BrainStorm to Present at Two Scientific Conferences in May
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present data from its Phase 2 clinical study of NurOwn in amyotrophic lateral sclerosis (ALS) at the International Society for
Brainstorm Cell Therapeutics to Present at ARM's 5th Annual Cell & Gene Therapy Investor Day, April 27 in Boston
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will present at the Alliance for Regenerative Medicine's (ARM) 5th Annual Cell & Gene Therapy Investor D
BrainStorm Announces Publication of NurOwn Autism Research Study
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that a preclinical study evaluating the use of NurOwn mesenchymal stem cells in a mouse model of autism was published in the April issue of the journ
BrainStorm Announces Financial Results for 2016 and Provides Business Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the year ended December 31, 2016.
BrainStorm CEO to Present at the Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide an update on new developments and a corporate overview at Sachs Associates 2nd Annual Neuro
BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today the appointment of Ralph Z. Kern, MD, MHSc to the positions of Chief Operating Officer and Chief Medical Officer, effective March 6, 2017. He joins Br
BrainStorm Announces MOU with Tel Aviv Sourasky Medical Center to Make NurOwn Available to Patients as a Hospital Exemption Product
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that is has signed a Memorandum of Understanding (MOU) with The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Sourasky Me
BrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial Success
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today the appointments of June S. Almenoff, M.D., Ph.D., FACP, and Arturo O. Araya, M.A., M.B.A. to its Board of Directors.
BrainStorm Seeking Approval To Distribute NurOwn in Canada
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, has signed an agreement with CCRM, a Toronto-based leader in developing and commercializing regenerative medicine technologies, and cell and gene therapies, to suppor
City of Hope to Manufacture NurOwn for Brainstorm's Phase 3 ALS Clinical Trial
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it plans to contract with City of Hope's Center for Biomedicine and Genetics to produce clinical supplies of NurOwn adult stem cells for the com
BrainStorm CEO to Present at the BIO CEO & Investor Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide a corporate overview at BIO CEO & Investor Conference, being held on February 13-14, 2017 a
BrainStorm Announces Validation of NurOwn Cryopreservation Process
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has validated its cryopreservation process for NurOwn in preparation for the upcoming Phase 3 clinical study in Amyotrophic Lateral Sclerosis (ALS)
BrainStorm CEO to Present at the Phacilitate Cell & Gene Therapy World Conference 2017 in Miami
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will give a presentation entitled "NurOwn – ground breaking treatment for ALS and other neurodegenerati
BrainStorm CEO to Present at the 9th Annual Biotech Showcase
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide a corporate overview at the 9th Annual Biotech Showcase, being held on January 9-11, 2017 a
Long term beneficial effect of neurotrophic factors-secreting mesenchymal stem cells transplantation in the BTBR mouse model of autism
Peer-reviewed preclinical study of MSC-NTF cell transplantation in the BTBR mouse model of autism.
Concise review: mesenchymal stem cells in neurodegenerative diseases
Peer-reviewed concise review of the use of mesenchymal stem cells in neurodegenerative diseases.
Brainstorm Reports on Successful End of Phase 2 Meeting with FDA, Upcoming Phase 3 Trial and Planned Application for Hospital Exemption for NurOwn
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today provided a corporate update and announced its clinical development objectives for 2017.
21st Century Cures Act Passed by U.S. Congress Provides an Accelerated Approval Pathway for Regenerative Medicine Therapies
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced its support for the 21st Century Cures Act. The Act, which has been passed by both houses of congress and is expected to be signed into law in the near future
In-Depth Analyses Presented at International Symposium on ALS/MND Suggest Strong Biological Effect for NurOwn; Evidence of Halting of Disease Progression
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that new data from the Company's Phase 2 study of NurOwn in ALS were presented by lead investigator Dr. James Berry at the 27th International Symposium on ALS/MND
BrainStorm to Host Year End Call with Investors to Discuss Important Corporate Developments
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call on December 19 at 8:30 am Eastern Time. Mr. Chaim Lebovits, BrainStorm's President and Chief Executive Officer, wi
BrainStorm Announces NurOwn Data to be Highlighted at the 27th International Symposium on ALS/MND
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today data from the Company's Phase 2 study of NurOwn in ALS, will be highlighted in presentations at the 27th International Symposium on ALS/MND, being held Decem
BrainStorm Cell Therapeutics Reports Third Quarter 2016 Financial Results
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the third quarter ended September 30, 2016.
BrainStorm Granted United States Patent for its Stem Cell Technology
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has been granted United States Patent No. 9,474,787 titled "Mesenchymal Stem Cells for the Treatment of CNS Diseases."
BrainStorm CEO to Present at Two Investor Conferences in September
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide a corporate overview at two upcoming investor conferences: The Rodman & Renshaw 18th Annual
BrainStorm Cell Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the second quarter ended June 30, 2016.
BrainStorm Announces Positive Top Line Results from the U.S. Phase 2 Study of NurOwn in Patients with Amyotrophic Lateral Sclerosis (ALS)
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced results from the recently completed U.S. randomized, double-blind, placebo-controlled phase 2 Study of NurOwn in Patients with ALS. The study achieve
BrainStorm to Announce Top Line Results from the U.S. Phase 2 Study of NurOwn in Patients with Amyotrophic Lateral Sclerosis (ALS) on Monday, July 18
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce results from the recently completed Phase 2 Study of NurOwn in Patients with ALS on Monday, July 18, 2016. The Company will host a conference call and
BrainStorm to Present at World Stem Cells & Regenerative Medicine Congress in London
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits, Chief Executive Officer, will be presenting Thursday, May 19 th, at the 11th World Stem Cells & Regenerative Medicine Congress in
BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2016 from Israel's Office of the Chief Scientist
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded a new grant of approximately $1,470,000 from Israel's Office of
BrainStorm Cell Therapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2016.
Brainstorm to Present at the ISRASTEM 2016 and the 6th International Israel Stem Cell Society Joint Annual Meeting
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Dr. Yael Gothelf, VP Scientific & Regulatory Affairs will be presenting at the ISRASTEM 2016 and the 6th Israel Stem Cell Society (ISCS) joint an
BrainStorm Announces Financial Results for 2015 and Provides Business Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2015. Brainstorm filed its annual report on Form 10-K reporting the results on Marc
BrainStorm to Present at Bio-Asia-International and ARM Investor Day Conferences
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits, Chief Executive Officer, will be presenting at two upcoming conferences.
BrainStorm's NurOwn for the Treatment of ALS Published in JAMA Neurology
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced the publication of a paper in the January 2016 edition of JAMA Neurology discussing the outcome of the first in man Phase 1/2 study and Phase 2 dose escalat
BrainStorm Cell Therapeutics to Conduct Phase 2 Multi-Dose NurOwn Trial in ALS at Hadassah Medical Center
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has entered into a collaborative agreement with Hadassah Medical Center in Jerusalem, Israel, to conduct the planned multi dose Phase 2 trial
Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis
Peer-reviewed report of the safety and clinical effects of MSC-NTF cell transplantation in participants with ALS.
BrainStorm Reschedules Corporate Update Conference Call to January 11, 2016
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has rescheduled its conference call, originally scheduled for Wednesday, December 16, 2015 to Monday, January 11, 2016, due to longer than exp
BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen-Aricha as Vice President of Research & Development
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Dr. Revital Geffen-Aricha, M.Sc., Ph.D., as Vice President of Research and Development. Dr. Geffen-Aricha will be based in Israe
BrainStorm Hosting Conference Call to Update Shareholders on Important Developments
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will hold a conference call on Wednesday, December 16, 2015 at 8:45 a.m. Eastern Standard Time (EST), 15:45 Israel Standard Time (IST). Mr. Ch
BrainStorm and Octane Biotech Announce Success in Cocoon™ Application Development Based on Customized Bioreactor for NurOwn Stem Cells
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, and Octane Biotech Inc., a Canadian company that focuses on clinical systems for cell and tissue therapy, announced today that they have made significant progress towa
BrainStorm Awarded Additional $735,000 Non-Dilutive Grant for 2015 from Israel's Office of the Chief Scientist
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded an additional grant of approximately $735,000 from Israel's Offi
BrainStorm Cell Therapeutics Reports Third Quarter 2015 Financial Results And Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the third quarter ended September 30, 2015.
BrainStorm Cell Therapeutics Announces Positive DSMB Review in Phase 2 Trial of NurOwn in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Data and Safety Monitoring Board (DSMB) conducted its second pre-planned safety review of the randomized, double-blind, placebo-controlled ph
BrainStorm Strengthens Intellectual Property Position - Granted Patent for Company's NurOwn Technology Platform
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Company has been granted a patent by the Israeli Patent Office for BrainStorm's application, titled "Isolated Population of Cells, Methods of
BrainStorm Cell Therapeutics' Chief Scientific Advisor to Present At The 2015 FENS-RM in Thessaloniki, Greece
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announces that its Chief Scientific Advisor, Prof Daniel Offen, PhD, will be presenting today at the 2015 Federation Of European Neuroscience Societies (FENS) Regional
BrainStorm Announces Treatment of Final Patient in US Multicenter Double Blinded Phase 2 ALS Trial
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the final patient has been treated in its multicenter Phase 2 clinical trial investigating the company's proprietary NurOwn™ stem cell technology
BrainStorm Cell Therapeutics to Present at 2015 Stem Cell Meeting on the Mesa
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will be presenting at the annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, California. Tony Fiorino, MD, PhD, wi
BrainStorm Announces Appointment of Chaim Lebovits as Chief Executive Officer
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Mr. Chaim Lebovits, who has been serving as the Company's President since July 2007, as Chief Executive Officer (CEO). Mr. Lebov
BrainStorm Cell Therapeutics to Present at Rodman & Renshaw 17th Annual Global Investment Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate update at the Rodman & Renshaw 17th Annual Global Investment Conference s
BrainStorm Cell Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the second quarter ended June 30, 2015.
BrainStorm Cell Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of NurOwn in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has completed enrollment in its ongoing randomized, double-blind placebo-controlled phase 2 clinical trial of NurOwn in amyotrophic lateral s
BrainStorm Cell Therapeutics to Report Second Quarter 2015 Financial Results on Thursday, August 13
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report second quarter 2015 financial results on Thursday, August 13, 2015. The Company will issue a press release before the market opens
BrainStorm Strengthens Executive Team: Announces the Appointment of Yoram Bibring as Chief Financial Officer
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Yoram Bibring as Chief Financial Officer, effective July 30, 2015. Mr. Bibring will be responsible for all corporate finance and
BrainStorm Cell Therapeutics to Present at Cantor Fitzgerald's Inaugural Healthcare Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate update at Cantor Fitzgerald's Inaugural Healthcare Conference on Wednesda
BrainStorm Cell Therapeutics Added to Russell Microcap® Index
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that has been added to the Russell Microcap® Index. The Russell indexes are reconstituted on an annual basis, with this year's process having conclude
BrainStorm Cell Therapeutics at the BIO International Convention
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, is participating in the Israel Pavilion at the invitation of Israel's Office of the Chief Scientist. BrainStorm is one of a small group of Israeli biopharmaceutical,
BrainStorm Cell Therapeutics Announces First Quarter 2015 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2015.
BrainStorm Cell Therapeutics to Present at Upcoming Conferences
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Dr. Yael Gothelf, Vice President, Scientific and Regulatory Affairs, will be presenting at the at IATI Biomed 2015 Conference and ISCT 2015 Annua
BrainStorm Cell Therapeutics to Report First Quarter 2015 Financial Results on Thursday, May 14
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report first quarter 2015 financial results on Thursday, May 14, 2015. The Company will issue a press release before the market opens and
BrainStorm's NurOwn Demonstrates a Statistically Significant Effect in ALS Patients
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, is presenting results from its phase 2a study of NurOwn in amyotrophic lateral sclerosis (ALS) at a poster session today at the American Academy of Neurology annual
BrainStorm Cell Therapeutics to Present Positive NurOwn Phase 2a Clinical Data at American Academy of Neurology Annual Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that results from its phase 2a study of NurOwn in amyotrophic lateral sclerosis (ALS) and additional analyses will be presented at the American Acade
BrainStorm Announces Financial Results for 2014 and Provides Business Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2014.
BrainStorm Cell Therapeutics to Report Fourth Quarter and Full Year 2014 Financial Results on Thursday, March 26
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report fourth quarter and full year 2014 financial results on Thursday, March 26, 2015. The Company will issue a press release before the
BrainStorm Cell Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25 in New York
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that CEO Tony Fiorino, MD, PhD, will present at the 3rd Annual Regen Med Investor Day to be held Wednesday, March 25, 2015 in New York City.
BrainStorm Receives Notice of Allowance for its NurOwn™ Technology Platform from Israel's Patent Office
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from Israel's Patent Office for its patent application titled "Isolated Population of Cells, Methods of Gen
BrainStorm CEO to Present at the 17th Annual BIO CEO & Investor Conference
HACKENSACK, N.J. & PETACH TIKVAH, Israel, Feb. 4, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chief Executive Officer Tony Fiorino, MD, PhD, will be presenting a corpor
BrainStorm Announces Positive DSMB Recommendation in Ongoing Phase 2 Trial with NurOwn™ in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Data and Safety Monitoring Board (DSMB) met to conduct its first safety review of the randomized, double-blind, placebo-controlled phase 2 cli
BrainStorm Announces Exceptional Preclinical Results of NurOwn™ in Mouse Autism Model
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive results from preclinical studies of NurOwn™ in the BTBR mouse model of autism. NurOwn™ cells are mesenchymal stem cells (MSCs) that have been
BrainStorm Enters Into Warrant Exercise Agreement for Approximately $13 Million in Proceeds
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has entered into a Warrant Exercise Agreement with certain holders of warrants issued in the June 13, 2014 private placement. These holders have ag
BrainStorm Announces Receipt of Approximately $3.1 Million from Warrant Exercises
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that since January 2, 2015 it has received approximately $3.1 million from the exercise of warrants for approximately 700 thousand shares, which were
BrainStorm CEO to Present at Two Upcoming Investor Conferences
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Tony Fiorino, MD, PhD, Chief Executive Officer, will be presenting at two upcoming investor conferences.
BrainStorm Announces Final Analysis of Phase 2a ALS Study Showing Nearly All Subjects Experienced Clinical Benefit from NurOwn™
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive final results from its phase 2a clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS) patients, which enrolled 14 subjects at Hadas
BrainStorm Cell Therapeutics to Host Conference Call to Discuss Final Results of Phase 2a Trial of NurOwn™ in ALS on January 5, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will release the final results from its phase 2a clinical trial of NurOwn™ in amytrophic lateral sclerosis (ALS) and hold a conference call and webcast to discuss the
BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office
NEW YORK & PETACH TIKVAH, Israel, Dec. 15, 2014 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant of
BrainStorm Announces Financial Results for the Third Quarter of 2014 and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three and nine months ending September 30, 2014.
BrainStorm Cell Therapeutics to Report Third Quarter 2014 Financial Results on Thursday, November 13
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report third quarter 2014 financial results on Thursday, November 13, 2014. The Company will issue a press release before the market opens and wi
FDA Grants Fast Track Designation to NurOwn™ for the Treatment of ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the United States Food and Drug Administration (FDA) has designated NurOwn™ as a Fast Track product for the treatment of amyotrophic lateral scle
BrainStorm Reports Last Patient Visit in Phase 2a ALS Study
BrainStorm Cell Therapeutics (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the last patient has completed the last visit in its phase 2a clinical trial of NurOwn™ in Amyotrophic Lateral Sclerosis (ALS), conducted at the Hadas
Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells
Peer-reviewed report on the safety of repeated transplantations of neurotrophic factor-secreting human mesenchymal stromal stem cells.
Rare combination of myasthenia and motor neuronopathy, responsive to MSC-NTFstem cell therapy
Peer-reviewed single-patient case report of a rare combination of myasthenia and motor neuronopathy treated with MSC-NTF cells.
Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2 transgenic mouse model for Huntington’s disease
Peer-reviewed preclinical study of intrastriatal MSC-NTF cell transplantation in the R6/2 transgenic mouse model of Huntington’s disease.
Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington’s disease
Peer-reviewed preclinical study of MSC-NTF cells and quinolinic acid toxicity as a potential therapy for Huntington’s disease.
Differentiated mesenchymal stem cells for sciatic nerve injury
Peer-reviewed preclinical study of differentiated mesenchymal stem cells in sciatic nerve injury.
Intravitreal injections of neurotrophic factors secreting mesenchymal stem cells are neuroprotective in rat eyes following optic nerve transection
Peer-reviewed preclinical study of intravitreal MSC-NTF cell injections in rat eyes following optic nerve transection.
Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis
Peer-reviewed preclinical study of intracerebroventricular MSC-NTF cell transplantation in a mouse model of multiple sclerosis.
Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease
Peer-reviewed preclinical study of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease.
Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases
Peer-reviewed paper on adult neurotrophic factor-secreting stem cells as a potential therapy for neurodegenerative diseases.
Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson’s disease
Peer-reviewed study of the induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells.
Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging
Peer-reviewed preclinical study tracking MSC-NTF cell migration toward a quinolinic acid lesion by magnetic resonance imaging.
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.